FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-04-07

Price

$14.47

+0.14%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is currently trading as a pure M&A arbitrage play following BioMarin's definitive agreement to acquire the company for $14.50 per share in cash. The stock's current price of $14.47 reflects a near-zero risk premium, driven by recent shareholder approval and the securing of FTC antitrust clearance. Technical signals like QUIET_STORM and STEADY_CLIMB perfectly capture the institutional arbitrage accumulation anchoring the price just below the deal ceiling. In the current RISK_ON geopolitical regime where the broader market is ignoring escalating Middle East tensions, this pending acquisition acts as a defensive cash proxy, completely insulating FOLD from macro volatility.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

M&AAnchor:BioMarin's$14.50all-cashbuyoutsetsahardceilingonthestock, explainingthetighttradingrangeandbroadanalystdowngradesto'Hold'[1.4].
Arbitrage Compression: Trading at $14.47, the spread is just 3 cents, indicating extreme market confidence in a seamless Q2 2026 deal close.
Macro Insulation: The pending deal makes FOLD effectively immune to current geopolitical and inflation shocks, acting as a safe haven for institutional capital.

← Back to 2026-04-07 View Full FOLD History →Yahoo Finance &nearr;